-transparent.png){kind=logo}
Data on the pharmacokinetics of antibiotics after inhalation are limited. The aim of this pilot study was to assess the pharmacokinetics of tobramycin under optimalized and standardized aerosol circumstances and, furthermore, to be able to consider possible treatment of exacerbations with inhalation therapy. Six patients were studied after inhalation of 600 mg tobramycin. A jet nebulizer loaded with a 10% solution of tobramycin in water was used. The percentage of the dose that was systemically absorbed ranged from 1.0% to 16.6%. The maximum serum levels of tobramycin ranged from 0.77 mg/L to 3.63 mg/L (mean 1.70 +/- 1.01). The pharmacokinetic data were best described by a two-compartment model. Compared to intravenous administration, the long terminal half-life (mean 9.47 h +/- 3.28 h) could be explained by the slow absorption of tobramycin from the site of administration (flip-flop model). Despite standardized aerosol conditions, considerable interpatient variability was observed. However, the relatively low serum levels allow a further increase of the dose.
P P Le Brun, and
A A Vinks, and
D J Touw, and
N Hekelaar, and
G P Mannes, and
R W Brimicombe, and
E H Frijlink, and
H G Heijerman
November 1999,
International journal of pharmaceutics,
P P Le Brun, and
A A Vinks, and
D J Touw, and
N Hekelaar, and
G P Mannes, and
R W Brimicombe, and
E H Frijlink, and
H G Heijerman
November 1999,
International journal of pharmaceutics,
P P Le Brun, and
A A Vinks, and
D J Touw, and
N Hekelaar, and
G P Mannes, and
R W Brimicombe, and
E H Frijlink, and
H G Heijerman
April 1997,
Chest,
P P Le Brun, and
A A Vinks, and
D J Touw, and
N Hekelaar, and
G P Mannes, and
R W Brimicombe, and
E H Frijlink, and
H G Heijerman
April 1981,
Chest,
P P Le Brun, and
A A Vinks, and
D J Touw, and
N Hekelaar, and
G P Mannes, and
R W Brimicombe, and
E H Frijlink, and
H G Heijerman
September 2005,
Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
P P Le Brun, and
A A Vinks, and
D J Touw, and
N Hekelaar, and
G P Mannes, and
R W Brimicombe, and
E H Frijlink, and
H G Heijerman
April 2005,
Therapeutic drug monitoring,
P P Le Brun, and
A A Vinks, and
D J Touw, and
N Hekelaar, and
G P Mannes, and
R W Brimicombe, and
E H Frijlink, and
H G Heijerman
June 1993,
Chest,
P P Le Brun, and
A A Vinks, and
D J Touw, and
N Hekelaar, and
G P Mannes, and
R W Brimicombe, and
E H Frijlink, and
H G Heijerman
May 1997,
Chest,
P P Le Brun, and
A A Vinks, and
D J Touw, and
N Hekelaar, and
G P Mannes, and
R W Brimicombe, and
E H Frijlink, and
H G Heijerman
January 2022,
Journal of pharmaceutical innovation,
P P Le Brun, and
A A Vinks, and
D J Touw, and
N Hekelaar, and
G P Mannes, and
R W Brimicombe, and
E H Frijlink, and
H G Heijerman
August 1987,
The American review of respiratory disease,
